RPRX:NSD-Royalty Pharma plc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 38.55

Change

+0.66 (+1.74)%

Market Cap

USD 16.17B

Volume

1.42M

Avg Analyst Target

USD 48.67 (+26.24%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Royalty Pharma plc (RPRX) Stock Analysis:
Based on the Royalty Pharma plc stock forecasts from 3 analysts, the average analyst target price for Royalty Pharma plc is USD 48.67 over the next 12 months. Royalty Pharma plc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Royalty Pharma plc is Neutral, which is based on 7 positive signals and 6 negative signals. At the last closing, Royalty Pharma plc’s stock price was USD 38.55. Royalty Pharma plc’s stock price has changed by -1.22 % over the past week, -0.97 % over the past month and -12.49 % over the last year.

About

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-07 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

+17.02 (+6.41%)

USD122.24B 18.38 14.64
BNTX BioNTech SE

+22.86 (+8.17%)

USD83.44B 8.87 7.65
REGN Regeneron Pharmaceuticals Inc

+10.09 (+1.61%)

USD68.31B 10.00 7.78
VRTX Vertex Pharmaceuticals Incorpo..

+0.16 (+0.08%)

USD51.82B 24.59 15.60
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

+18.04 (+6.03%)

USD33.26B N/A N/A
SGEN Seagen Inc

+0.43 (+0.29%)

USD27.56B 55.02 44.86
GMAB Genmab A/S

+1.82 (+4.93%)

USD24.43B 55.83 6.05
ALNY Alnylam Pharmaceuticals Inc

+3.28 (+1.85%)

USD20.49B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing RPRX

Symbol Name Weight Mer Price(Change) Market Cap

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -21.17% 60% D- 28% F
Dividend Return 1.39% 40% F 33% F
Total Return -19.78% 61% D- 28% F
Trailing 12 Months  
Capital Gain -12.49% 65% D 30% F
Dividend Return 1.54% 60% D- 32% F
Total Return -10.94% 67% D+ 30% F
Trailing 5 Years  
Capital Gain 9,912.99% 99% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 9,912.99% 99% A+ 99% A+
Average Annual (5 Year Horizon)  
Capital Gain 5.82% 43% F 43% F
Dividend Return 0.12% 8% F 3% F
Total Return 5.94% 43% F 38% F
Risk Return Profile  
Volatility (Standard Deviation) 38.58% 74% C 47% F
Risk Adjusted Return 15.40% 45% F 29% F
Market Capitalization 16.17B 98% A+ 94% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 19.67 32% F 44% F
Price/Book Ratio 2.79 54% F 42% F
Price / Cash Flow Ratio 7.95 8% F 40% F
EV/EBITDA 11.86 26% F 54% F
Management Effectiveness  
Return on Equity 15.40% 96% A 80% B-
Return on Invested Capital 13.77% 88% B+ 83% B
Return on Assets 6.14% 95% A 83% B
Debt to Equity Ratio 120.71% 11% F 17% F
Technical Ratios  
Short Ratio 3.13 60% D- 45% F
Short Percent 2.09% 74% C 57% F
Beta 0.69 76% C 76% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.